Search
Sanofi Receives Approval in China for Trelagy, an Innovative Drug to Delay Type 1 Diabetes Progression
2 week ago /
Read about 0 minute
Author：小编
Sanofi has announced the approval of its teplizumab injection, marketed as Trelagy, by China's National Medical Products Administration. This groundbreaking medication is indicated for use in children aged 8 and older, as well as adults, with Type 1 Diabetes at Stage 2. Trelagy aims to delay the progression of the disease to the more severe Stage 3 by addressing the root cause and preserving pancreatic islet function, thereby offering patients a novel therapeutic approach.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
